Shelby Saunders

Cooley advised Vance Street Capital, a Los Angeles-based middle-market private equity firm that invests in highly engineered solutions businesses across the industrial technology, medical, life sciences, aerospace and defense sectors, on its acquisition of System Seals, a designer and manufacturer of custom fluid seals for various industrial applications.

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.

Cooley advised Halcyon on its $100 million Series C funding. Partner Derek Colla led the Cooley team advising Halcyon, an organization devoted to defeating ransomware through prevention and resilience by way of a proprietary technology that captures encryption keys, enabling organizations to recover from attacks in minutes without paying ransom.

Cooley advised Cresta, an end-to-end generative artificial intelligence (AI) platform for contact centers, on the closing of its $125 million Series D.

Cooley advised early-stage venture capital firm RPM Ventures as the lead investor for Firefly Aerospace's oversubscribed $175 million Series D.